Supernus Pharmaceuticals, Inc. (SUPN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Supernus Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Supernus Pharmaceuticals, Inc. (SUPN) has returned 4.00% so far this year and 57.83% over the past 12 months. Over the last decade, SUPN has posted an annualized return of 12.30%, slightly higher than the S&P 500 Index benchmark’s 12.16%.

Based on dividend-adjusted daily data since May 1, 2012, SUPN's average daily return is +0.12%, while the average monthly return is +2.23%. At this rate, your investment would double in approximately 2.6 years.

Historically, 56% of months were positive and 44% were negative. The best month was Jun 2012 with a return of +70.5%, while the worst month was Nov 2012 at -30.3%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.

On a daily basis, SUPN closed higher 51% of trading days. The best single day was Jun 26, 2012 with a return of +114.2%, while the worst single day was Nov 6, 2019 at -31.6%.

Supernus Pharmaceuticals, Inc. has an annualized alpha of 23.85%, beta of 0.80, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since May 02, 2012.

• This stock captured 114.45% of S&P 500 Index gains but only 86.57% of its losses — a favorable profile for investors.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SUPN ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Supernus Pharmaceuticals, Inc. (SUPN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Supernus Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Supernus Pharmaceuticals, Inc. was 75.86%, occurring on Mar 18, 2020. The portfolio has not yet recovered.

The current Supernus Pharmaceuticals, Inc. drawdown is 13.63%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Supernus Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Supernus Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.